Skip to main content

Table 1 Clinical, demographic and serologic data of 55 patients with and without synovitis

From: Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers

  All (n = 55) Ultrasound-defined active synovitis P valuea
Yes (n = 25) No (n = 30)
Age (years) 52.0 (44.0 to 61.5) 51.0 (44.0 to 59.0) 55.0 (47.0 to 63.3) 0.279
Sex (male) 13 (23.6%) 8 (32.0%) 5 (16.7%) 0.311
Body mass index 25.2 (23.2 to 28.3) 26.0 (24.0 to 29.0) 24.0 (23.1 to 27.4) 0.122
Disease duration (months) 90.0 (57.1 to 148.9) 86.3 (60.3 to 153.8) 93.7 (54.9 to 145.2) 0.659
Remission duration (months) 37 (8 to 58) 29 (7.50 to 50.00) 37 (9.00 to 66.25) 0.537
DAS28-ESR 2.03 (1.67 to 2.44) 2.24 (1.94 to 2.55) 1.92 (1.56 to 2.16) 0.060
DAS28-CRP 1.42 (1.38 to 1.58) 1.54 (1.39 to 1.67) 1.40 (1.23 to 1.48) 0.023
SDAI 4.51 (3.56 to 6.21) 5.03 (4.11 to 7.70) 4.14 (2.69 to 6.02) 0.064
Patient global assessment 30 (10 to 30) 30 (10 to 30) 30 (10 to 30) 0.767
Physician global assessment 10 (10 to 30) 10 (10 to 30) 10 (10 to 30) 0.322
VAS pain 9 (2 to 25) 14 (4 to 23) 5 (2 to 25) 0.251
VAS fatigue 15 (2 to 47) 14 (0 to 43) 16 (3 to 57) 0.529
mHAQ 0.1 (0.0 to 0.3) 0.1 (0.0 to 0.3) 0.0 (0.0 to 0.3) 0.570
ESR (mm/1 hour) 9 (7 to 15) 10 (7 to 20) 9 (6 to 12) 0.498
CRP (mg/dl) 0.10 (0.03 to 0.33) 0.11 (0.03 to 0.49) 0.09 (0.04 to 0.23) 0.728
Rheumatoid factor 39 (71%) 18 (72%) 21 (70%) 0.900
Rheumatoid factor (IU) 103 (22 to 229) 84 (22 to 240) 113 (23 to 215) 0.980
ACPA 47 (86%) 23 (92%) 24 (80%) 0.383
ACPA titers (IU/ml) 254 (109 to 1575) 270 (121 to 1352) 226 (83 to 1600) 0.645
Prednisone 15 (27%) 3 (12%) 12 (40%) 0.044
DMARDs 45 (82%) 22 (88%) 23 (77%) 0.463
Biological therapy 23 (42%) 9 (36%) 14 (47%') 0.600
SH (grade ≥2) 31 (56%) 25 (100%) 6 (20%) <0.001
PDUS 35 (64%) 25 (100%) 10 (33%) <0.001
  1. Data expressed as median (interquartile range) or as number (percentage). ACPA, anti-cyclic citrullinated peptide/protein antibody; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; mHAQ. Modified Health Assessment Questionnaire; PDUS, power Doppler ultrasound; SDAI, Simplified Disease Activity Index; SH, synovial hypertrophy; VAS, visual analog scale. aMann–Whitney test.